S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Chemoradiotherapy
/ methods
Cisplatin
/ administration & dosage
Clinical Trials, Phase II as Topic
Drug Combinations
Humans
Middle Aged
Multicenter Studies as Topic
Oxonic Acid
/ administration & dosage
Prognosis
Research Design
Tegafur
/ administration & dosage
Thymoma
/ pathology
Thymus Neoplasms
/ pathology
Young Adult
Cisplatin
S-1
radiotherapy
thymic carcinoma
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
25
11
2019
revised:
29
12
2019
accepted:
29
12
2019
pubmed:
6
2
2020
medline:
6
3
2021
entrez:
6
2
2020
Statut:
ppublish
Résumé
Thymic carcinoma is a rare epithelial tumor of the thymus with a poor prognosis, and multimodal approaches are important for its treatment. Recently, a number of studies have indicated that S-1 treatment is effective against thymic carcinoma. S-1 plus cisplatin with concurrent radiotherapy is a commonly used treatment for other malignancies, including non-small cell lung cancer (NSCLC). In addition, its safety has been confirmed, and it has been reported to have a marked effect against thymic carcinoma. Therefore, we conducted a phase II study of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced thymic carcinoma, in which the overall response rate was employed as the primary endpoint. The secondary endpoints were overall survival, progression-free survival, and safety.
Identifiants
pubmed: 32020735
doi: 10.1111/1759-7714.13319
pmc: PMC7049479
doi:
Substances chimiques
Drug Combinations
0
S 1 (combination)
150863-82-4
Tegafur
1548R74NSZ
Oxonic Acid
5VT6420TIG
Cisplatin
Q20Q21Q62J
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
693-696Informations de copyright
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Cancer Res. 1996 Jun 1;56(11):2602-6
pubmed: 8653704
Lung Cancer. 2015 Feb;87(2):141-7
pubmed: 25534129
Br J Cancer. 2018 Sep;119(6):675-682
pubmed: 30206369
Lung Cancer. 2004 Apr;44(1):69-77
pubmed: 15013585
Br J Cancer. 2001 Sep 28;85(7):939-43
pubmed: 11592762
J Thorac Oncol. 2008 Sep;3(9):1076
pubmed: 18758317
Int J Oncol. 2000 Oct;17(4):653-8
pubmed: 10995874
J Thorac Oncol. 2010 Apr;5(4):572-3
pubmed: 20357624
Anticancer Res. 2014 Oct;34(10):5743-7
pubmed: 25275083
Lung Cancer. 2020 Jan;139:89-93
pubmed: 31751805
Lung Cancer. 2010 Dec;70(3):357-63
pubmed: 20951466